(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
World leaders, rights groups react to COP30 climate deal - 2‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today
- 3As world leaders enter climate talks, people in poverty have the most at stake
- 4Flu activity rises sharply across US with 7.5 million cases, CDC data shows
- 5Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- Hoist Your Style: Famous Hairdos for Ladies
- Public Parks in the USA
- Vote In favor of Your Favored Language Interpretation Administration
- Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual
- In these U.S. groups, deaths now exceed births. What’s happening?
- ‘Wu-Tang Forever: The Final Chamber’ tour — How to get tickets, presale times, concert dates and more
- One dead, six wounded in various crime-related shootings in Israel over the weekend
- Rights group: At least 2,500 deaths during protest crackdown in Iran
- Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie
